How dependent is India on Cardiovascular APIs (Atorvastatin, Rosuvastatin) imports?

India imports $0.35 bn, mostly from China. Its Critical Manufacturing Dependency Index is 71.25/100 (High), with a localisation potential of 59.5.

Cardiovascular APIs (Atorvastatin, Rosuvastatin)

High dependencyBuild-nowPharmaceuticals & APIsReasoned estimateHS 2933.39

$0.35 bnAnnual import

25%Indian capability

5,300Supplier concentration (HHI)

₹1,800 crTo localise

Why India imports it. China dominates statin KSM; India strong in API (Biocon, Sun).

Why it matters. Cardiovascular disease burden in India.

Can India localise it? Yes - 3-5 years.

Where it comes from. China (70%), India (20%), Italy (10%).

Scorecard

CMDI 71.25Dependency

LPI 59.5Localisation potential

IAI 66.25Investment attractiveness

SRI 68.5Supply risk

SCI 50.75Supply-chain complexity

TRI 40.75Technology readiness

IMI 66.5Industrial multiplier

NSRI 59National-security relevance

EPI 65.25Export potential

ICGI 59.75Capability gap

Who makes it

Biocon LtdSun Pharmaceutical IndustriesMylan

Huaheng ChemicalNcpc

On the ground

Bulk Drug Park - Haroli (Himachal)Cipla Ltd · himachal-pradesh · under construction · ₹5,000 cr

Intelligence

Sources

Confidence: Reasoned estimate. Reasoned estimate. Part of Techadyant Labs' Critical Manufacturing Dependencies (Edition I).